无钙枸橼酸盐透析液行无肝素局部抗凝延长间歇性血液透析在重症患者中的研究
该前瞻性队列研究纳入35例需肾脏替代治疗的重症患者,共完成101次透析 sessions(机械通气78次,去甲肾上腺素13次)。采用含枸橼酸盐无钙透析液、按离子透析率补充钙的无肝素局部抗凝方案,中位透析时间294分钟,中位超滤量2.3 L。尿素和β2-微球蛋白下降率分别为64.5%±0.4%和48%±0.13%,滤器后离子钙在1小时和3小时分别为0.35±0.17和0.38±0.14 mmol/L。仅3/101次 sessions 因主要凝血事件提前终止,且这3例在回路凝血前已发生导管功能严重障碍。作者认为该方案简便、有效、廉价,无需全身监测离子钙,可根据血流动力学耐受性安全延长 sessions。
要点
- 35例重症患者共101次透析 sessions 中,仅3次(3/101)因主要凝血事件提前终止,且这3例在回路凝血前已发生导管功能严重障碍。
- 中位透析时间294分钟(IQR 240-300),中位超滤量2.3 L(IQR 1-2.8),尿素下降率64.5%±0.4%,β2-微球蛋白下降率48%±0.13%。
- 滤器后离子钙在1小时和3小时分别为0.35±0.17和0.38±0.14 mmol/L,滤器前离子钙变化仅+0.07±0.006 mmol/L,总钙/离子钙比值不变。
- 该方案无需全身监测离子钙,sessions 可根据血流动力学耐受性安全延长,以保证足够透析剂量和负水平衡。
适用人群与场景
- 重症监护病房中需要肾脏替代治疗的重症患者,包括机械通气(78次 sessions)和使用去甲肾上腺素(13次 sessions)者。
- 出血风险高、需要延长间歇性透析且需要无肝素抗凝替代方案的患者。
处置流程与药物剂量
- 使用含枸橼酸盐的无钙透析液进行局部枸橼酸抗凝,并根据离子透析率补充钙。
- 透析 sessions 可根据血流动力学耐受性安全延长,中位持续时间294分钟(IQR 240-300),中位超滤量2.3 L(IQR 1-2.8)。
- 无需全身监测离子钙。
红旗征与不能漏的情况
- 导管功能严重障碍可先于回路凝血发生,本研究中3例因主要凝血事件提前终止的 sessions 均在回路凝血前已出现导管功能严重障碍。
研究设计与关键结果
- 前瞻性队列研究,35例重症患者共完成101次透析 sessions;机械通气78次,使用去甲肾上腺素13次。
- 中位透析时间294分钟(IQR 240-300),中位超滤量2.3 L(IQR 1-2.8)。
- 尿素下降率64.5%±0.4%,β2-微球蛋白下降率48%±0.13%。
- 滤器后离子钙1小时为0.35±0.17 mmol/L,3小时为0.38±0.14 mmol/L;滤器前离子钙变化+0.07±0.006 mmol/L,总钙/离子钙比值不变。
- 仅3/101次 sessions 因主要凝血事件提前终止,且这3例在回路凝血前已发生导管功能严重障碍。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于出血高风险、需要延长间歇性透析的重症患者,该无肝素局部枸橼酸抗凝方案(含枸橼酸盐无钙透析液+按离子透析率补钙)可简便、有效、廉价地完成透析,无需全身监测离子钙。
- 作者认为 sessions 可根据血流动力学耐受性安全延长,以保证足够透析剂量和负水平衡,这对严重急性肾损伤患者尤为重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Critically ill patients who have a high risk of bleeding but require prolonged intermittent dialysis need a heparin-free easy-to-use alternative type of anticoagulation within the dialysis circuit. We assessed the safety and efficiency of heparin-free regional citrate anticoagulation of the dialysis circuit using a calcium-free citrate-containing dialysate, with calcium reinjected according to ionic dialysance.
DESIGN: Prospective cohort study.
SETTING: Critical care units.
PATIENTS: Critically ill patients who required renal replacement therapy.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: A total of 101 dialysis sessions were performed in 35 patients (mechanical ventilation n = 78; norepinephrine n = 13). Median duration of dialysis was 294 minutes (interquartile range, 240-300), and median ultrafiltration volume was 2.3 L (1-2.8). Urea and β2-microglobulin reduction rates were 64.5% ± 0.4% and 48% ± 0.13%, respectively. Postfilter ionized calcium was 0.35 ± 0.17 and 0.38 ± 0.14 mmol/L at 1 and 3 hours, respectively, within the extracorporeal circuit. A major clotting event that led to premature termination of the session occurred in only three of 101 sessions. In these three cases, major catheter dysfunction occurred before clotting within the circuit. Prefilter ionized calcium remained within narrow ranges (before/after change +0.07 ± 0.006 mmol/L), and total-to-ionized calcium ratio, a surrogate marker for citratemia, was unchanged.
CONCLUSIONS: Dialysis anticoagulation with calcium-free citrate-containing dialysate and calcium reinjection according to ionic dialysance is an easy-to-use, efficient, and inexpensive form of heparin-free regional anticoagulation. It allows prolonged hemodialysis sessions in critically ill patients without the need to systemically monitor ionized calcium. Furthermore, sessions can be safely extended according to the hemodynamic tolerance to ensure an adequate dose of dialysis and a negative water balance, a major point in patients with severe acute kidney disease.
参考来源
- Faguer S, Saint-Cricq M, Nogier MB, et al. Heparin-Free Prolonged Intermittent Hemodialysis Using Calcium-Free Citrate Dialysate in Critically Ill Patients. Crit Care Med. 2017. PMID: 28857854. doi:10.1097/CCM.0000000000002694
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。